LOPRESSOR (metoprolol tartrate) by Bausch Health is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for hypertension in adult patients, to lower blood pressure, the long-term treatment of angina pectoris and 7 more indications. First approved in 1978.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
Lopressor (metoprolol tartrate) is an oral beta-1 selective adrenergic receptor blocking agent used to treat hypertension, angina pectoris, and acute myocardial infarction. It works by competitively antagonizing catecholamines at cardiac adrenergic sites, reducing heart rate, cardiac contractility, and blood pressure. The drug's beta-1 selectivity provides cardioselective benefits with reduced respiratory effects compared to non-selective beta-blockers.
The product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition planning for generic transition.
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Worked on LOPRESSOR at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants
Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg
Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Lopressor offers experience in mature-market brand defense, generic transition management, and payer negotiations in a highly competitive legacy cardiovascular segment. Limited growth trajectory means career advancement depends on operational excellence and portfolio diversification rather than new indication launches.